Table 2.

Unadjusted and adjusted FEV1 percent predicted by genotype. #

	N,% * (BLx, NHC)	Delta FEV1 percent predicted unadjusted (CI)**	p	Delta FEV1 percent predicted adjusted (CI)	p
Heterozygous F508	9 (23%), 97 (43%)	− 16.92 (− 33.01, − 0.82)	0.040	− 15.57 (− 32.31, 1.16)	0.068
Homozygous F508	13 (38%), 59 (28%)	− 4.60 (− 18.77, 9.55)	0.520	− 0.67 (− 17.42, 16.08)	0.937
No F508 mutation	13 (38%), 49 (24%)	− 11.70 (− 27.21, 3.82)	0.137	− 9.65 (− 25.15, 7.84)	0.273

^*Missing data in 22 patients

^**Reflects difference in FEV1 percent predicted of BLx group compared with NHC

^# Patients’ gender, age, age at diagnosis, presence of diabetes, median household income based on zip code of residence, and insurance type (private/Medicare vs. public (Medicaid)) were included in the model to adjust for potential confounding